Development of dual aptamers-functionalized c-MET PROTAC degraders for targeted therapy of osteosarcoma

Q: What does this research mean for the field?

AS1411-SL1 chimeras function as effective c-MET PROTAC degraders and represent a promising targeted therapy for osteosarcoma. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

Xuekun Fu; Jie Huang; Xinxin Chen; Duoli Xie; Hongzhen Chen; Zhijian Liang; Zhuqian Wang; Yiying Liang; Aiping Lü; Chao Liang

doi:10.7150/thno.99588

December 2, 2024TheranosticsOpen Access

Development of dual aptamers-functionalized c-MET PROTAC degraders for targeted therapy of osteosarcoma

View Full Paper

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

This study suggests that the AS1411-SL1 chimeras could be promising c-MET degraders for targeted therapy of OS.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Fu et al. (2024) studied this question.

synapsesocial.com/papers/6a1c93450e2acd31eb2fe357 https://doi.org/10.7150/thno.99588

View Full Paper

Ask AI

Bookmark

Share

Development of dual aptamers-functionalized c-MET PROTAC degraders for targeted therapy of osteosarcoma

Ask about this paper

Abstract

Discussion

Cite This Study

Development of dual aptamers-functionalized c-MET PROTAC degraders for targeted therapy of osteosarcoma

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading